| Literature DB >> 25929572 |
Young-Dong Kim1, Tae-Eun Park, Bijay Singh, Sushila Maharjan, Yun-Jaie Choi, Pill-Hoon Choung, Rohidas B Arote, Chong-Su Cho.
Abstract
Lung cancer is one of the most lethal diseases worldwide, and the survival rate is less than 15% even after the treatment. Unfortunately, chemotherapeutic treatments for lung cancer are accompanied by severe side effects, lack of selectivity and multidrug resistance. In order to overcome the limitations of conventional chemotherapy, nanoparticle-mediated RNA interference drugs represent a potential new approach due to selective silencing effect of oncogenes and multidrug resistance related genes. In this review, we provide recent advancements on nanoparticle-mediated siRNA delivery strategies including lipid system, polymeric system and rigid nanoparticles for lung cancer therapies. Importantly, codelivery of siRNA with conventional anticancer drugs and recent theranostic agents that offer great potential for lung cancer therapy is covered.Entities:
Keywords: RNA interference; codelivery system; lung cancer; nanoparticle; siRNA delivery system
Mesh：
Substances：
Year: 2015 PMID： 25929572 DOI： 10.2217/nnm.14.214
Source DB: PubMed Journal: Nanomedicine (Lond) ISSN： 1743-5889 Impact factor: 5.307